The development of anti-PD-1/PD-L1 monoclonal antibodies has recently become a hot topic in cancer immunotherapy, thereby dramatically changing the therapeutic approaches for many cancers at an advanced stage [11]. The gene discussed is PDCD1; the disease is cancer.